A first in man phase I study of EPC2407, a microtubule inhibitor anti-cancer drug with tumor vascular endothelial disrupting activity: intravenous administration daily for three days in patients with advanced solid tumors and lymphomas

Trial Profile

A first in man phase I study of EPC2407, a microtubule inhibitor anti-cancer drug with tumor vascular endothelial disrupting activity: intravenous administration daily for three days in patients with advanced solid tumors and lymphomas

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2009

At a glance

  • Drugs Crolibulin (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Immune Pharmaceuticals Inc
  • Most Recent Events

    • 15 Sep 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 15 May 2008 Interim results data will be reported at ASCO 2008, according to a media release from EpiCept.
    • 07 Apr 2008 Positive results are reported in a EpiCept Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top